Dimethyl Fumarate Market; Increasing Prevalence of Multiple Sclerosis to Propel Market Growth

Dimethyl Fumarate (DMF) is a chemical compound that belongs to the class of fumaricaq acid esters. It is primarily used in the pharmaceutical industry as a medication for the treatment of certain autoimmune diseases, most notably multiple sclerosis (MS). DMF was initially used as a food preservative due to its antimicrobial properties. However, its therapeutic potential in managing autoimmune disorders was discovered during studies on psoriasis, a chronic skin condition.

Dimethyl Fumarate Market has demonstrated efficacy in the treatment of relapsing forms of multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. The prevalence of MS has been increasing globally, resulting in a higher demand for effective and well-tolerated treatment options. This growing patient population has created a significant market for MS therapies, including DMF. As a result, pharmaceutical companies have invested in the development, manufacturing, and marketing of DMF to meet the demand.

The report “Dimethyl Fumarate Market, By Type (Dimethyl Fumarate 97% and Dimethyl Fumarate 98%), By Application (Food, Drink, Feed, Pharmaceutical, and Cosmetic), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In June 2022, Sandoz expands its portfolio and launched the generic drug “Dimethyl Fumarate HEXAL” and also it is given approval for the treatment of adults with relapsing remitting multiple sclerosis (RRMS) in Germany. For patients to have access to high-quality and reasonably priced medications, Sandoz is dedicated to creating and supplying generic therapeutics. According to Peter Stenico, head of Sandoz Germany and CEO of Hexal AG, "Hexal will no longer only make this available in symptomatic therapy, but also for the first time with dimethyl fumarate for the course-modifying treatment of multiple sclerosis in adults."
• In September 2020, Dr Reddy’s Laboratories Ltd. released Dimethyl Fumarate Delayed-Release Capsules, a generically approved, therapeutically comparable version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules. For the most recent twelve months, the Tecfidera® brand and the generic market had combined U.S. sales of almost $3.8 billion MAT. Dimethyl fumarate delayed-release capsules from Dr. Reddy's come in 120 mg and 240 mg strengths. Biogen has trademarked Tecfidera.
• In October 2020, Pharma major Lupin Limited (Lupin) announced that it has received approval for its Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg, from the United States Food and Drug Administration (US FDA) to commercialize a generic version of Biogen, Inc.'s Tecfidera® Delayed-Release Capsules, 120 mg and 240 mg.

Analyst View:

Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system. The global prevalence of MS is rising, creating a larger patient pool requiring effective treatment options. As DMF has shown efficacy in managing relapsing forms of MS, the growing patient population is expected to drive the demand for Dimethyl Fumarate Market in the future. Market dynamics are subject to various uncertainties, including regulatory changes, competition from other treatment options, and emerging therapies. However, based on the current trends and the growing demand for effective treatments for autoimmune diseases, including MS, the Dimethyl Fumarate (DMF) Market is expected to experience continued growth in the foreseeable future.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Dimethyl Fumarate Market, By Type (Dimethyl Fumarate 97% and Dimethyl Fumarate 98%), By Application (Food, Drink, Feed, Pharmaceutical, and Cosmetic), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Dimethyl Fumarate Market is segmented based on Type, Application and Region.

• Based on Type, Dimethyl Fumarate Market is segmented into Biopharmaceutical and Chemistry Medicine.
• Based on Application, Dimethyl Fumarate Market is segmented into Hospital and Clinic.
• By Region, the Dimethyl Fumarate Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Dimethyl Fumarate Market:

The prominent players operating in the Dimethyl Fumarate Market includes, Pfizer, Inc., Roche, Inc., Sanofi, Inc., Johnson & Johnson, Merck & Co. (MSD), Novartis AG, AbbVie, Inc., Gilead Sciences, GlaxoSmithKline (GSK), Amgen and others.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- [email protected]

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com